SHARE THIS VIDEO —
CEO behind HIV drug Truvada grilled on $3B in profits
Catch up with NBC News Clone on today's hot topic: Mmvo59819077674 - Breaking News | NBC News Clone. Our editorial team reformatted this story for clarity and speed.
Daniel O’Day, the chairman and CEO of Gliead Sciences Inc., is asked to explain U.S. pricing of HIV prevention drug Truvada for PrEP along with his company’s profits and his $30M signing bonus.
Want more summaries like this? Follow NBC News Clone for expertly filtered news from trusted sources.
